Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Share-based Compensation (2016 - 2025)

International Stem Cell (ISCO) has disclosed Share-based Compensation for 16 consecutive years, with $63000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 37.0% to $63000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $324000.0, a 34.68% decrease, with the full-year FY2024 number at $466000.0, changed 0.43% from a year prior.
  • Share-based Compensation was $63000.0 for Q3 2025 at International Stem Cell, up from $61000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $234000.0 in Q1 2021 to a low of $61000.0 in Q2 2025.
  • A 5-year average of $115631.6 and a median of $109000.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: crashed 61.11% in 2022, then increased 26.85% in 2024.
  • International Stem Cell's Share-based Compensation stood at $120000.0 in 2021, then fell by 9.17% to $109000.0 in 2022, then rose by 19.27% to $130000.0 in 2023, then dropped by 23.08% to $100000.0 in 2024, then plummeted by 37.0% to $63000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Share-based Compensation are $63000.0 (Q3 2025), $61000.0 (Q2 2025), and $100000.0 (Q1 2025).